EuCorVac 19
Alternative Names: EuCorVac-19Latest Information Update: 27 Jun 2024
At a glance
- Originator EuBiologics
- Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Phase III COVID 2019 infections
Most Recent Events
- 09 Feb 2024 EuBiologics completes a phase-III trial in COVID-2019 infections (Prevention) in Philippines (IM) (NCT05572879)
- 15 Jan 2024 EuBiologics completes the phase III trial in COVID-2019 infections (Prevention) in Congo (IM) (NCT05603052)
- 27 Sep 2022 EuBiologics completes a phase-I/II clinical trials in COVID-2019 infections (Prevention) in South Korea (IM) (NCT04783311)